Full name
Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment With Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B Virus (B-Well 1)
NCT Number
NCT05630807
Geography
US
Non-US
Locations
Argentina, Brazil, Bulgaria, Canada, China, France, Germany, Greece, Hong Kong. Hungary, India, Italy, Japan, Republic of Korea, Malaysia, Mexico, Panama, Poland, Romania, Singapore, Spain, Taiwan, Thailand, Turkey, United Kingdom, United States
Primary Endpoints
Number of participants achieving functional cure (FC) with baseline HBsAg ≤3000 IU/mL. Up to 72 weeks
Order
1
Disease
Version
Phase
3
Status
Active, not recruiting